10-Q: Kintara Therapeutics Reports Q2 2024 Results, Focuses on REM-001 After VAL-083 Setback

Kintara Therapeutics reported a net loss for the second quarter of fiscal year 2024 and is shifting its focus to the REM-001 program after discontinuing development of VAL-083.

Summary

• Kintara Therapeutics reported a net loss of $1.02 million for the three months ended December 31, 2023, and a net loss of $3.98 million for the six months ended December 31, 2023.
• The company's cash and cash equivalents stood at $658,000 as of December 31, 2023.
• Kintara has discontinued the development of VAL-083 after it failed to perform better than current standards of care in a clinical trial.
• The company is now focusing on its REM-001 program for cutaneous metastatic breast cancer (CMBC), supported by a $2 million grant from the National Institutes of Health.
• Kintara is exploring strategic alternatives to maximize stockholder value.
• The company has raised $2.579 million through its at-the-market (ATM) facility and $105,000 through a purchase agreement with Lincoln Park during the six months ended December 31, 2023.
• The company has received a notice from Nasdaq for not complying with the minimum stockholders equity and minimum bid price requirements.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, the failure of a key drug candidate, and non-compliance with Nasdaq listing requirements, leading to a negative sentiment. However, the company is actively pursuing new funding and has a promising program in REM-001.

Positives

• Kintara received a $2 million grant from the NIH to support the clinical development of REM-001.
• The company has re-initiated the REM-001 program and expects to start enrolling patients in the first quarter of calendar year 2024.
• Kintara has raised additional capital through its ATM facility and a purchase agreement.
• The company has initiated a process to explore strategic alternatives to maximize stockholder value.
• A 15-patient clinical trial for REM-001 in CMBC was initiated on February 12, 2024.

Negatives

• Kintara reported a net loss of $1.02 million for the three months ended December 31, 2023, and a net loss of $3.98 million for the six months ended December 31, 2023.
• The company's cash and cash equivalents were $658,000 as of December 31, 2023.
• The development of VAL-083 has been terminated after it failed to show improved results in a clinical trial.
• Kintara received a notice from Nasdaq for not complying with the minimum stockholders equity and minimum bid price requirements.
• There is substantial doubt about the company's ability to continue as a going concern within one year.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial situation.
• Kintara may not be able to raise sufficient additional capital to fund its operations.
• The company is not in compliance with Nasdaq's minimum stockholders equity and minimum bid price requirements, which could lead to delisting.
• The company's future success depends on the successful development and commercialization of its product candidates, which is uncertain.
• The company faces risks related to clinical trials, regulatory approvals, and competition.

Future Outlook

The company plans to focus on the REM-001 program and is exploring strategic alternatives to maximize stockholder value. They will need to raise additional capital to continue operations.

Management Comments

• Management is pursuing various financing alternatives to fund the company's operations.
• Management plans to secure necessary financing through potential additional proceeds from the Lincoln Park agreement, the ATM facility, grant funding, and the issue of new equity or strategic partnerships.
• The company has initiated a process to explore and review a range of strategic alternatives focused on maximizing shareholder value.

Industry Context

The company's shift in focus from VAL-083 to REM-001 reflects the challenges in developing effective cancer therapies and the need to prioritize promising candidates. The company's focus on orphan cancer indications aligns with a growing trend in the pharmaceutical industry to address unmet medical needs in rare diseases.

Comparison to Industry Standards

• Kintara's decision to terminate VAL-083 after disappointing trial results is a common occurrence in the biotech industry, where clinical trial failures are frequent.
• The company's focus on REM-001, a photodynamic therapy, is a less common approach compared to traditional chemotherapy or targeted therapies, but it aligns with the industry's interest in exploring novel treatment modalities.
• The company's financial situation, with limited cash reserves and ongoing losses, is not uncommon for clinical-stage biotech companies, which often rely on external funding to support their operations.
• The company's need to raise additional capital is typical for biotech companies at this stage, and the use of ATM facilities and strategic partnerships are common strategies for securing funding.
• The company's non-compliance with Nasdaq listing requirements is a concern, as it could lead to delisting and negatively impact the company's ability to raise capital. Many small cap biotech companies face similar challenges.

Management Changes

Related Party Transactions

• Valent Technologies, LLC is a related party due to Dr. Brown's principal role and the Patent Assignment Agreement.
• The company paid dividends to Valent related to the Series A Preferred Stock.
• There is an aggregate amount of $148,000 payable to the company's officers and directors for fees, expenses, and accrued bonuses and other liabilities.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential delisting from Nasdaq.
• Employees may be affected by cost-cutting measures and potential changes in the company's direction.
• Patients with CMBC may benefit from the development of REM-001.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will focus on the REM-001 program and start enrolling patients in the REM-001 Study in the first quarter of calendar year 2024.
• The company will explore strategic alternatives to maximize stockholder value.
• The company will seek additional funding through various means, including the ATM facility, the Lincoln Park agreement, and strategic partnerships.
• The company will work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Kintara Therapeutics, REM-001, VAL-083, CMBC, clinical trial, photodynamic therapy, cancer therapy, NIH grant, Nasdaq, going concern